Glutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjects by Venketaraman, Vishwanath et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
AIDS Research and Therapy
Open Access Research
Glutathione and growth inhibition of Mycobacterium tuberculosis 
in healthy and HIV infected subjects
Vishwanath Venketaraman*1,2,3,4,5,6, Tatanisha Rodgers1,4,6, Rafael Linares6, 
Nancy Reilly1,4,6, Shobha Swaminathan1,4,6, David Hom2,6, 
Ariel C Millman1,4,6, Robert Wallis1,4,6,7 and Nancy D Connell1,2,3,4,5,6
Address: 1Division of Infectious Diseases, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA, 2Center for Emerging and Re-emerging 
Pathogens, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA, 3National Tuberculosis Center, UMDNJ-New Jersey Medical School, 
Newark, NJ 07103, USA, 4Department of Medicine, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA, 5Department of Microbiology 
and Molecular Genetics, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA, 6New Jersey Medical School, UMDNJ-New Jersey Medical 
School, Newark, NJ 07103, USA and 7PPD, 1213 N Street NW, Apt. A, Washington DC 20005, USA
Email: Vishwanath Venketaraman* - venketvi@umdnj.edu; Tatanisha Rodgers - rodgerto@umdnj.edu; 
Rafael Linares - rafael_a.linares@roche.com; Nancy Reilly - reillyna@umdnj.edu; Shobha Swaminathan - swaminsh@umdnj.edu; 
David Hom - homdl@umdnj.edu; Ariel C Millman - millmaac@umdnj.edu; Robert Wallis - wallis@umdnj.edu; 
Nancy D Connell - connell@umdnj.edu
* Corresponding author    
Abstract
Intracellular levels of glutathione are depleted in patients with acquired immunodeficiency
syndrome in whom the risk of tuberculosis, particularly disseminated disease is many times that of
healthy individuals. In this study, we examined the role of glutathione in immunity against
tuberculosis infection in samples derived from healthy and human immunodeficiency virus infected
subjects. Our studies confirm that glutathione levels are reduced in peripheral blood mononuclear
cells and in red blood cells isolated from human immunodeficiency virus-infected subjects
(CD4>400/cumm). Furthermore, treatment of blood cultures from human immunodeficiency virus
infected subjects with N-acetyl cysteine, a glutathione precursor, caused improved control of
intracellular M. tuberculosis infection. N-acetyl cysteine treatment decreased the levels of IL-1, TNF-
α, and IL-6, and increased the levels of IFN-γ in blood cultures derived from human
immunodeficiency virus-infected subjects, promoting the host immune responses to contain M.
tuberculosis infection successfully.
Introduction
Tuberculosis (TB) is a major global health problem [7].
Approximately one-third of the world's population is
latently infected with Mycobacterium tuberculosis (LTBI).
Individuals with LTBI have a 5–10% lifetime risk of devel-
oping active disease [7]. Human immunodeficiency virus
(HIV) infected subjects with LTBI are at very high risk of
developing active tuberculosis. Development of active TB
in HIV patients is due not only to reactivation of latent M.
tuberculosis infection but also due to increased susceptibil-
ity to primary progressive M. tuberculosis infection [7].
Innate and adaptive immune responses are required for
successful control of M. tuberculosis infection. Macro-
phages provide first line defense against M. tuberculosis
infection. Murine macrophages can be activated to kill
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intracellular M. tuberculosis by treatment with LPS (a stim-
ulus for TNF-α expression, via triggering of toll-like recep-
tors) and IFN-γ (a product of activated lymphocytes).
Nitric oxide (NO) produced by infected macrophages is
the main mediator (effector molecule) in this process.
Like those of mice, human macrophages also acquire
antimycobacterial activity through IFN-dependent inter-
actions with lymphocytes [12]. However, exogenous IFN-
γ does not enhance the mycobactericidal activity of iso-
lated human macrophages as it does those of mice. Sev-
eral studies indicate instead that direct cellular contact is
required for the induction of antimycobacterial activity in
human macrophages [6,33], and that this activity reflects
caspase-mediated induction of apoptosis, triggering of
toll-like receptors, the release of antibiotic peptides (e.g.,
granulysin), or unknown mechanisms [4,36].
Glutathione (GSH) is an antioxidant and plays a vital role
in cellular detoxification and enhancement of immune
functions [10]. Interestingly, HIV-infected people have
subnormal GSH levels in their plasma, lung epithelial lin-
ing fluid, peripheral blood mononuclear cells (PBMC),
and other blood cells [5,11,14,23]. It has been recently
reported that the decreased GSH levels in PBMC of HIV-
infected individuals is associated with a poorer prognosis
[24]. Immunodeficiency due to HIV-1 represents the
greatest recognized threat to successful containment of
latent M. tuberculosis infection. The aim of this study was
to examine the role of GSH in immunity against TB in
samples derived from healthy and HIV infected subjects.
In our previous studies using macrophages from different
sources, we have demonstrated that GSH plays a vital role
in innate immunity against TB infection [40,41]. In our
recent studies we have shown that GSH has static effect on
H37Rv growth in vitro [41]. The mechanism of toxicity of
GSH to mycobacteria is not yet known. One possibility is
that the presence of high concentrations of GSH may
result in an imbalance in a bacterial cell already contain-
ing an alternative thiol for regulating reduction/oxidation
activity (e.g., mycothiol).
In the present study, we reexamined the extent to which
GSH levels are decreased in HIV positive subjects. We also
examined the relationship between GSH levels and the
ability to kill intracellular M. tuberculosis, in association
with other immune functions, such as cytokine produc-
tion. GSH levels were modulated by treating blood sam-
ples with N-acetyl cysteine (NAC) to increase or
buthionine sulphoximine (BSO) to decrease intracellular
GSH pools. Our results suggest that the inability of
immune cells from healthy and HIV subjects to contain
TB growth may be a consequence of the inability of their
macrophages to maintain adequate GSH levels during in
vitro infection.
Experimental methods
Subjects
A total of 20 subjects (10 healthy volunteer controls and
10 patients with HIV infection) were enrolled at UMDNJ-
University Hospital of Newark and the NJ Medical School,
in Newark, NJ. Subjects with HIV infection without tuber-
culosis (n = 10) were recruited at the Infectious Disease
Clinic of UMDNJ-University Hospital. The Clinic is the
site of several ongoing studies of HIV treatment; these
studies provide anti-retroviral treatment (ART) to enrolled
subjects without charge. Patient care was not altered by
participation in this study. Patients were defined as being
HIV-positive on the basis of a positive ELISA with a con-
firmatory Western Blot performed as part of their routine
care in the clinic. The average CD4 numbers for HIV
patients in this study was 423 ± 83/cumm. Only one
patient had CD4 counts below 200/cumm. Seven patients
were on ART and three patients were not on any treatment
at the time of blood draw. Healthy subjects without HIV
infection or a history of TB were recruited from the hospi-
tal and the university faculty and staff (n = 10). Healthy
and HIV-positive subjects with a history of a positive
tuberculin test (TST) were excluded from the study so as
to maintain strict study definitions. This is according to
the CDC recommendation that recognizes that a positive
TST reflects latent TB infection.
Safety precautions for handling M. tuberculosis
All experiments with M. tuberculosis H37Rv were per-
formed inside the bio safety level 3 (BSL-3) facility. The
protocols for all experiments were approved by the
UMDNJ Institutional Review Board, and the New Jersey
Medical School Institutional Biosafety Committee. All
experimental procedures were performed inside the
biosafety cabinets in the BSL-3. All liquid and solid wastes
from the experiments were treated with a disinfectant
solution and then autoclaved.
Processing of H37Rv for infection
M. tuberculosis H37Rv was grown in 7H9 with albumin-
dextrose complex (ADC). Static cultures of mycobacteria
at peak logarithmic phase of growth (between 0.5 and 0.8
at A600) were used for infection. The bacterial suspension
was washed and resuspended in RPMI containing AB
serum. Bacterial clumps were disaggregated by vortexing
five times with 3-mm sterile glass beads. The bacterial sus-
pension was passed through a 5 µm filter to remove any
further clumps. The total number of organisms in the sus-
pension was determined by plating. Processed mycobacte-
ria were frozen as stocks at -80°C. At the time of infection,
frozen stocks of processed mycobacteria were thawed and
used for macrophage infection.AIDS Research and Therapy 2006, 3:5 http://www.aidsrestherapy.com/content/3/1/5
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Separation of monocytes from human blood
Human monocyte-derived macrophages (HMDM) were
used to study the effects of IFN-γ and GSH in inducing
intracellular killing of H37Rv. These experiments were
performed only in blood samples from healthy subjects
due to the non-availability of sufficient blood volume
from HIV patients. Forty ml of blood from healthy sub-
jects were used for monocyte isolation. PBMC were iso-
lated by ficoll hypaque density centrifugation. PBMC were
washed with PBS and resuspended in RPMI containing
5% AB serum. PBMC (10 × 106/ well) were distributed
into Poly-DL-lysine coated 12 well plates and incubated
overnight at 37°C, 5% CO2 in a humidified atmosphere,
to allow monocytes to adhere to the plate. Non-adherent
cells were removed by gentle washing and the adherent
monocytes were cultured in RPMI containing 5% AB
serum for 7 days before being used for infection experi-
ments to allow differentiation to macrophages. The total
number of macrophages per well (on day seven) was
quantitated by detaching the macrophages from a single
well by the addition of ice-cold accutase (Sigma). Viable
detached macrophages were counted in a Neubauer
counting chamber by trypan blue dye exclusion. The aver-
age number of macrophages per well on day 7 is approxi-
mately 5 × 105.
Macrophage infection
HMDM from healthy subjects were maintained in vitro as
described above. Macrophages were infected with proc-
essed H37Rv at moi of 10:1. Macrophages were incubated
with H37Rv for 2 h (for phagocytosis), after which extra-
cellular organisms were removed by washing with PBS.
Infected macrophages were maintained in RPMI contain-
ing 5% AB serum. Infected macrophage cultures were ter-
minated at 4 h and 7 days after infection and treatment, to
measure the intracellular viability of H37Rv. Cell free
supernatants from infected macrophage cultures were
diluted and plated for extracellular bacterial growth. Intra-
cellular viability of H37Rv was determined by lysing the
infected macrophages with sterile distilled water and plat-
ing the lysate on 7H11 enriched with ADC, to enumerate
mycobacterial colonies.
Survival of H37Rv in IFN-γ, LPS treated HMDM
IFN-γ is considered a predominant activator of microbi-
cidal functions in macrophages and is essential for pre-
vention of uncontrolled progression of M. tuberculosis
infection [2,18,27]. We therefore studied the survival of
H37Rv in IFN-γ, LPS treated HMDM. HMDM were main-
tained in vitro and infected with H37Rv, as described pre-
viously. H37Rv-infected HMDM were treated with IFN-γ
Growth of H37Rv in unstimulated (Fig 1a), IFN-γ, LPS (Fig 1a), and NAC treated HMDM (Fig 1b) Figure 1
Growth of H37Rv in unstimulated (Fig 1a), IFN-γ, LPS (Fig 1a), and NAC treated HMDM (Fig 1b). Human mono-
cytes from peripheral blood were maintained in vitro in RPMI containing 5% AB serum, for 7 days for differentiation to macro-
phages. HMDM were infected with H37Rv at moi of 10:1 and maintained in media alone (Fig 1a) or in media containing IFN-γ, 
LPS (100 U/ml and 1 µg/ml), respectively, (Fig 1a) or media containing, NAC 10 mM (Fig 1b). Infected macrophages were ter-
minated at 4 h & 7 d after infection to determine the intracellular growth of H37Rv. Intracellular colony counts of H37Rv were 
determined by plating lysed cultures on Middlebrook 7H11. Fig 1a, are means from six different experiments performed in trip-
licate. Fig 1b, are means from three different subjects performed in triplicate. (Fig 1c) Whole blood Infection of H37Rv. 
Blood from healthy individuals was diluted at the following proportion, 300 µl of blood was diluted to 1 ml with RPMI. One mil-
liliter of diluted blood was added to each well of 12 well tissue culture plates. Blood cultures were treated with none or NAC 
(10 mM) or NAC, BSO (500 µM) for 24 h. Blood cultures were infected with processed H37Rv. Infected blood cultures were 
terminated at 2 h & 48 h after infection, to determine the intracellular viability of H37Rv. Intracellular viability of H37Rv was 
determined by plating the diluted blood cell lysates on 7H11. Data in Figure 1c are averages from seven subjects performed in 
triplicate.
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(100 U/ml) and LPS (1 µg/ml), the cultures were termi-
nated at 4 h and 7 days after infection and treatment, to
determine the intracellular viability of H37Rv inside
unstimulated and IFN-γ, LPS-stimulated macrophages.
Survival of H37Rv inside NAC treated HMDM
We determined the effects of GSH in human macrophage
mediated growth inhibition of intracellular H37Rv.
HMDM were treated with different concentrations of
NAC. Cysteine uptake is considered as rate-limiting step
for synthesis of GSH. The most efficient way to increase
the levels of cysteine in cells grown in vitro is to supply the
culture medium with NAC. NAC is easily taken up by the
cells and is non-toxic. Intracellularly, NAC is de-acetylated
and cysteine is utilized for GSH synthesis. H37Rv infected
HMDM were treated with 5, 10, 15, and 20 mM NAC, and
intracellular growth of H37Rv was studied. Infected mac-
rophage cultures were terminated at 4 h and 7 days, after
infection and treatment. Infected macrophages were lysed
and plated for mycobacterial colonies.
Whole blood mycobactericidal assay
Mycobacteria added to heparinized blood (after dilution
with tissue culture medium), are rapidly ingested by
monocytes and other phagocytic cells such as neutrophils.
This model differs from other intracellular infection mod-
els in that all blood elements are represented. Interactions
of infected monocytes with natural killer cells and anti-
gen-specific T cells result in control of intracellular
growth. In contrast to the studies with isolated macro-
phages, the whole blood assay requires a low volume of
blood. Blood was diluted at the following proportion:
300 µl of blood from healthy subjects and patients were
diluted to 1 ml with RPMI. Blood cultures were infected
with 105 CFU of H37Rv. GSH levels in blood cultures were
altered using agents such as NAC (10 mM) and BSO (500
µM) that specifically increase and decrease intracellular
GSH. The effect of altered GSH levels on M. tuberculosis
survival was studied. Treatment of cells with BSO causes
inhibition of GSH synthesis. BSO specifically inhibits the
activity of γ-glutamyl-cysteinyl synthetase enzyme, that
catalyses the first step reaction in the synthesis of GSH.
Blood cultures were treated with either NAC or combina-
tion of NAC and BSO for 24 h prior to infection. H37Rv
infected whole blood cultures were incubated at 37°C
and harvested at selected intervals (2 h and, 48 h) by sed-
imentation at 2000 rpm for 10 min. Supernatants were
used to determine cytokine levels and extracellular myco-
bacterial growth. Host cells were disrupted by addition of
sterile water. The lysates were plated on 7H11 medium
enriched with ADC for mycobacterial colonies.
Assay of GSH
Intracellular GSH levels in PBMC, red blood cells (RBC),
and plasma, from healthy individuals and HIV positive
subjects were assayed by spectrophotometry, using a GSH
assay kit procured from Calbiochem. This approach is
used to determine whether GSH levels are decreased in all
Spectrophotometric assay of GSH in PBMC (Fig 2a) and RBC (Fig 2b), derived from healthy and HIV positive subjects Figure 2
Spectrophotometric assay of GSH in PBMC (Fig 2a) and RBC (Fig 2b), derived from healthy and HIV positive 
subjects: GSH assay kit was procured from Calbiochem. PBMC and RBC lysates (from HIV-infected and healthy subjects), 
were mixed with equal volume of ice cold 5% metaphosphoric acid (MPA) and centrifuged at 3000 rpm for 15 minutes. Super-
natants were used for GSH assay, as per manufacturer's instruction. Samples were also used for protein assay by Bradford's 
method using Bio Rad reagent.
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blood components or just in some specific components.
Plasma and cell lysates of RBC and PBMC, derived from
healthy and HIV positive subjects, were mixed with equal
volume of ice cold 5% metaphosphoric acid (MPA) and
centrifuged at 3000 rpm for 15 minutes. Supernatants
were used for GSH assay, as per the manufacturer's
instruction. Plasma, RBC, and PBMC were separated from
whole blood by density gradient centrifugation using
ficoll hypaque. Samples were also used for protein assay
by Bradford's method using Bio Rad reagent.
Cytokine assay
Blood cultures were prepared by afore mentioned meth-
ods. Blood cultures from healthy subjects and HIV
patients were treated as follows: no treatment, infection
with H37Rv, and infection with H37Rv and treatment
with NAC. Cultures were terminated at 2 h and 48 h, after
infection. Uninfected cultures were terminated at the
same time points. Cultures were centrifuged at 2000 rpm
for 10 min. Cell free supernatants from healthy and HIV
patients were used for the cytokine assay, which was per-
formed using a Beadlyte kit procured from Upstate. This is
a highly sensitive kit that can be used to detect multiple
cytokines in tissue culture samples. A monoclonal anti-
body specific for a cytokine is covalently linked to a fluo-
rescent bead set, which captures the cytokine. A
complementary biotinylated monoclonal cytokine anti-
body then completes the immunological sandwich and
the reaction is detected with streptavidin-phycoerythrin
using a Luminex. The assay was performed as per the man-
ufacturer's protocol.
Statistical analysis
Statistical analysis of the data was carried out using
Statview program and the statistical significance was
determined using unpaired t test. Data from cytokine
assays was analyzed by non-parametric test (Kruskal-wal-
lis). Differences were considered significant at a level of p
< 0.05.
Results
Survival of H37Rv in HMDM
We studied the survival of H37Rv in HMDM from healthy
subjects. H37Rv-infected HMDM were treated with IFN-γ
(100 U/ml) and LPS (1 µg/ml), and the intracellular via-
bility of H37Rv inside unstimulated and IFN-γ, LPS-stim-
ulated macrophages was compared. Figure 1a shows
results from six different subjects performed in triplicate.
We observed significant growth of H37Rv inside unstim-
ulated HMDM between 1 h and 7 days (Fig 1a). The
increase was almost four fold. Stimulation of HMDM cells
with IFN-γ, LPS also resulted in significant growth of intra-
cellular H37Rv (Fig 1a). However, the increase in H37Rv
growth was less than three-fold (Fig 1a). To examine
whether GSH plays a major role in human macrophage
killing of H37Rv, HMDM from healthy volunteers were
treated with 5, 10, 15, and 20 mM NAC, and intracellular
growth of H37Rv was measured. Experiments performed
in six different subjects show that treatment of HMDM
with 10 mM NAC resulted in stasis in H37Rv growth in
three out of six subjects (Fig 1b). Treatment of HMDM
with NAC at 5 mM and 15 mM induced growth inhibition
of H37Rv, in one out of six, and two out of six subjects,
Growth of H37Rv in whole blood cultures of HIV patients Figure 3
Growth of H37Rv in whole blood cultures of HIV patients. Blood from HIV positive subjects was diluted at the follow-
ing proportion, 300 µl of blood was diluted to 1 ml with RPMI. One milliliter of diluted blood was added to each well of 12 well 
tissue culture plates. Blood cultures were treated with none (Fig 3a), or 10 mM NAC (Fig 3b) or NAC, 500 µM BSO, (Fig 3c) 
for 24 h. Blood cultures were infected with processed H37Rv. Infected blood cultures were terminated at 2 h & 48 h after 
infection, to determine the intracellular viability of H37Rv. Intracellular viability of H37Rv was determined by plating the diluted 
blood cell lysate on 7H11. Data in Figure 3a, b, and c, are averages from four, eight and three subjects, respectively.
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respectively (data not shown). Treatment with 20 mM
NAC had no effect on growth inhibition of H37Rv (data
not shown). Therefore, NAC at 10 mM is more effective in
inducing growth control of M. tuberculosis as compared to
IFN-γ, LPS, or other concentrations of NAC (Fig 1b) in iso-
lated HMDM.
Whole blood model
Several studies indicate that direct cell contact is required
for induction of antimycobacterial activity in human mac-
rophages [6,33], and that this activity reflects caspase-
mediated induction of apoptosis, triggering of toll-like
receptors, the release of antibiotic peptides (e.g., granu-
lysin), or unknown mechanisms [4,36]. Mycobacteria are
IL-1, TNF-α, IL-6 and IFN-γ assays in blood culture supernatants Figure 4
IL-1, TNF-α, IL-6 and IFN-γ assays in blood culture supernatants: Blood cultures from HIV patients were treated as 
follows, no treatment, infection with H37Rv, and infection with H37Rv and treatment with NAC. Cultures were terminated at 
48 h, after infection. Uninfected cultures were terminated at the same time points. Cultures were centrifuged at 2000 rpm for 
10 min. Cell free supernatants were used for assay of IL-1 (Fig 4a), TNF-α (Fig 4b), IL- 6 (Fig 4c) and IFN-γ (Fig 4d). Cytokine 
assay was performed using a Beadlyte kit procured from Upstate. The assay was performed as per manufacturer's protocol.AIDS Research and Therapy 2006, 3:5 http://www.aidsrestherapy.com/content/3/1/5
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rapidly ingested by phagocytic cells when added to
heparinized blood (after dilution with tissue culture
medium). This model differs from other intracellular
infection models in that all blood elements are repre-
sented.
We therefore tested whether interaction of monocytes
with other immune cells will lead to growth inhibition of
intracellular H37Rv using whole blood cultures, which
provides a micro-environment that is conducive for cellu-
lar interactions.
Whole blood mycobactericidal assay in healthy subjects
Blood from healthy volunteers was diluted as described
and treated with none or 10 mM NAC. The blood cultures
were then infected with 5 × 105 CFU of processed H37Rv.
Infected blood cultures were terminated at 2 h and 48 h
after infection to determine the intracellular viability of
H37Rv. Cell suspensions were centrifuged to separate the
cell free supernatants and pellets. Supernatants were
diluted and plated for extracellular bacterial growth. Intra-
cellular viability of H37Rv was determined by plating the
diluted blood cell lysates on 7H11. Infection of blood cul-
tures with H37Rv resulted in almost two-fold increases in
the intracellular growth of H37Rv (Fig 1c). The increase in
H37Rv growth was statistically significant. Treatment of
blood cultures with NAC (10 mM), caused growth inhibi-
tion of H37Rv in all seven individuals tested (Fig 1c). The
data in Fig 1c are averages from seven healthy subjects.
Treatment of cultures with BSO abrogated the growth
inhibition effect of NAC (Fig 1c). These results indicate
that growth inhibition of H37Rv in NAC treated blood
cultures is due to combination of direct antimycobacterial
effects of GSH and activation of immune cells induced by
GSH.
Levels of GSH in blood samples from healthy and HIV-
positive subjects
Intracellular GSH levels in PBMC and RBC were assayed
by spectrophotometry as described. We observed a signif-
icant and more than 50% decrease in intracellular GSH
levels in PBMC (Fig 2a) and RBC (Fig 2b) from HIV
patients compared to healthy subjects. Data shown in Fig
2 are averages from six healthy and six HIV-infected sub-
jects. We observed no difference in the plasma GSH levels
between healthy and HIV patients.
Growth control of H37Rv by NAC-treated blood cultures 
from HIV patients
Intracellular growth of H37Rv was monitored in blood
cultures of HIV-positive subjects. We observed a signifi-
cant growth of H37Rv in unstimulated blood cultures (Fig
3a). NAC treatment induced growth inhibition of intrac-
ellular of H37Rv. Data in Fig 3b are averages from data
obtained from eight different HIV-positive subjects. BSO
IL-10 assay in blood culture supernatants Figure 5
IL-10 assay in blood culture supernatants: Blood cultures from healthy subjects and HIV patients were treated as 
described previously. Cultures were terminated at 48 h, after infection. Cell free supernatants, from healthy (Fig 5a), and HIV 
patients (Fig 5b), were used for assay of IL-10. Cytokine assay was performed using a Beadlyte kit procured from Upstate. Data 
in Figure 5a and b are averages from four healthy and five HIV-infected subjects, respectively.AIDS Research and Therapy 2006, 3:5 http://www.aidsrestherapy.com/content/3/1/5
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treatment abrogated the inhibitory effect brought about
by NAC treatment (Fig 3c).
Assay of cytokines in blood culture supernatants from 
healthy and HIV-positive subjects
Cytokines were measured in blood culture supernatants
from healthy and HIV-infected subjects. Interestingly, in
HIV subjects, H37Rv infection induced the blood cultures
to produce increased levels of pro-inflammatory cytokines
such as IL-1, TNF-α, and IL-6 (Fig 4a, 4b, 4c). H37Rv
infection induced almost three fold increases in IL-1 pro-
duction, compared to uninfected controls (Fig 4a). NAC
treatment of H37Rv infected cultures down-regulated IL-1
levels (Fig 4a). Compared to uninfected controls, H37Rv
infection induced seven fold increases in TNF-α levels in
two patients tested (Fig 4b). NAC treatment of H37Rv
infected cultures caused reduction in TNF-α levels (Fig
4b). H37Rv infection induced almost ten fold increases in
IL-6 production, in three patients tested (Fig 4c). NAC
treatment reduced the levels of IL-6 to those found in the
uninfected control. We also observed that infection of
HIV blood cultures with H37Rv caused six fold increases
in IFN-γ production in two patients and three fold
increases in one patient (Fig 4d). In comparison to
untreated controls, NAC treatment of H37Rv infected cul-
tures induced ten fold increases in IFN-γ production in
two patients and almost four fold increases in one patient
(Fig 4d). In summary, our studies show that NAC treat-
ment down-regulated the synthesis of IL-1, IL-6, and TNF-
α and increased the levels of IFN-γ (Fig 4a, 4b, 4c, 4d).
With the exception of IL-10, all other cytokines produced
by healthy subjects showed no clear trend. The regulation
of IL-10 synthesis in response to H37Rv infection and
NAC treatment was similar in healthy subjects and HIV
patients. H37Rv induced almost ten-fold increases in IL-
10 levels in both healthy and HIV-infected subjects (Fig
5a, 5b). Furthermore, NAC treatment reduced the levels of
IL-10 to those found in uninfected controls, in both
healthy subjects and HIV patients (Fig 5a, 5b).
Discussion
Development of TB in HIV infected patients is based on a
predisposition to reactivation of latent M. tuberculosis
infection and to susceptibility to primary progressive M.
tuberculosis  infection [9]. However, the relationship of
host immune responses to the development of TB during
different stages of HIV disease is not clear. The opportun-
istic behavior of M. tuberculosis during human HIV infec-
tion can be explained by suppression of type-1 responses
at the level of antigen-presenting cells, CD4 T cells and
effector macrophages.
In vitro studies have shown that lowering of intracellular
GSH levels decreases cell survival, alters T cell functions
and increases HIV replication, NF-kB activation, and sen-
sitivity to TNF-α induced cell death [10,11,19]. A role has
also been proposed for GSH as a carrier molecule for NO.
Nitric oxide also reacts with GSH to form GSNO, an NO
donor with greater stability [34,35].
We first reported that GSH facilitates the control of intra-
cellular  M. bovis BCG in NO-deficient macrophages
derived from iNOS knock out mice, and in HMDM [40].
These studies indicated that GSH has direct antimycobac-
terial activity distinct from its role as an NO carrier. Fur-
Model describing direct and indirect effects of GSH in growth control of H37Rv in blood cultures derived from healthy and  HIV-infected subjects Figure 6
Model describing direct and indirect effects of GSH in growth control of H37Rv in blood cultures derived from 
healthy and HIV-infected subjects. (Fig B) Model describing the effect GSH in modulating cytokine synthesis in whole 
blood cultures derived from HIV positive subjects.
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thermore, in our recent studies we demonstrated that GSH
is vital for growth control of intracellular H37Rv in J744.1
macrophages [41].
It has been reported that production of IFN-γ is crucial to
the control of M. tuberculosis infection [18]. Impaired pro-
duction of IFN-γ correlates with progression of immuno-
deficiency and is likely related to abnormalities in the IL-
12-IFN-γ axis [8,31]. We therefore tested the growth of
H37Rv in HMDM from healthy subjects that are unstimu-
lated or stimulated in vitro with IFN-γ, LPS. We observed a
significant, four-fold increase in growth of H37Rv inside
unstimulated HMDM, between 1 h and 7 days (Fig 1a).
Stimulation of H37Rv-infected HMDM cells with IFN-γ,
LPS also resulted in a three-fold increase in growth of
intracellular H37Rv (Fig 1a). Since our earlier studies sug-
gested a role for GSH in innate immunity against M. tuber-
culosis, we tested whether NAC treatment would induce
HMDM to inhibit the growth of H37Rv. We observed that
NAC at 10 mM concentration induced growth inhibition
of H37Rv in three out of six healthy individuals tested (Fig
1b). Although normal levels of GSH are present in cells
derived from healthy subjects, those levels might decrease
during oxidative and nitrosative stress generated during
TB infection. Therefore, addition of NAC to HMDM
caused growth inhibition of M. tuberculosis by augmenting
intracellular GSH levels. These results suggest that growth
inhibition of H37Rv in NAC treated HMDM is due to the
direct antimycobacterial effects of GSH. Furthermore, the
inability of HMDM from some healthy individuals to
inhibit M. tuberculosis growth is probably due to the ina-
bility of macrophages to maintain adequate GSH levels,
despite NAC treatment.
As described before, innate and adaptive immunity are
essential for successful elimination of M. tuberculosis. Mac-
rophages interact with other immune cells in vivo, for suc-
cessful growth retardation of M. tuberculosis. The whole
blood model of infection resembles an in vivo system in
promoting cellular interactions. This model differs from
other intracellular infection models in that all blood ele-
ments are represented. Infection of blood cultures from
healthy volunteers with H37Rv resulted in an almost two-
fold increase in H37Rv growth (Fig 1c). The increase in
H37Rv growth was statistically significant. In contrast to
HMDM, treatment of blood cultures with NAC (10 mM)
caused growth inhibition of H37Rv, in all seven individu-
als tested (Fig 1c). Our results suggest that growth inhibi-
tion of H37Rv in NAC treated blood cultures is due to
direct antimycobacterial effects of GSH and due to activa-
tion of blood cells induced by GSH.
We have confirmed the work of others that GSH levels are
decreased in patients with HIV-1 infection [5,11,14,23],
and then hypothesized that this decrease would be associ-
ated with reduced capacity of monocytes to kill intracellu-
lar  M. tuberculosis. We further proposed that NAC
treatment would improve the killing of M. tuberculosis. We
tested our hypothesis by determining GSH levels in
healthy and HIV positive subjects. We observed a signifi-
cant and more than 50% decrease in GSH levels in PBMC
and RBC from HIV patients compared to healthy subjects
(Fig 2a, 2b). Since GSH enhances innate and adaptive
immune functions, GSH deficiency in PBMC may contrib-
ute to the progressive immune dysfunction of HIV infec-
tion. Macrophages play a central role in HIV and TB
infection because they are among the first cells to be
infected [19]. Moreover, macrophages serve as an impor-
tant reservoir for both HIV and M. tuberculosis. The major
obstacle to eradication of HIV is latent virus in these res-
ervoirs which has prompted the search for new drugs and
strategies to protect this cell compartment. Erythrocytes
have been used as a carrier system to deliver antiretroviral
molecules to macrophages selectively. Fraternale et al [19]
have reported that treatment of mice with
AZT+DD1+GSH-loaded RBC significantly reduces the
proviral DNA content, compared to mice treated with
AZT+DD1. This result is consistent with our hypothesis
and suggests that low levels of GSH in RBC, as observed in
this and other studies, will affect the GSH carrier functions
of RBC, compromising GSH delivery to macrophages.
In order to determine the effects of NAC treatment on
PBMC and RBC in reducing the growth of intracellular
H37Rv, whole blood cultures from HIV patients were
treated in vitro with NAC and infected with H37Rv. We
observed significant growth of H37Rv in unstimulated
blood cultures from HIV patients (Fig 3a). In vitro NAC
treatment to blood cultures derived from HIV subjects
caused inhibition in growth of intracellular H37Rv (Fig
3b). Furthermore, BSO treatment abrogated the inhibi-
tory effect brought about by NAC treatment (Fig 3c). This
suggests that restoration of GSH levels in HIV subjects
caused enhancement in immune cell functions to contain
M. tuberculosis growth.
The decreased GSH content in immune cells of HIV-posi-
tive individuals was atleast in part attributed to the
decreased in plasma cysteine and increased plasma gluta-
mate (an inhibitor of cysteine permeation via the Xc-
transport system), as observed during early infection. The
decreased intracellular GSH and plasma cysteine observed
in HIV patients is due to chronic oxidative stress, which
may lead to the progression of the disease. The decreased
availability of cysteine can be overcome to some extent by
the cysteine precursor NAC [13]. A recent report of a care-
fully conducted clinical trial indicates that NAC treatment
improves the clinical situation and delays the HIV disease
progression [24]. This study showed that long-term
administration of NAC to AIDS patients improves theirAIDS Research and Therapy 2006, 3:5 http://www.aidsrestherapy.com/content/3/1/5
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hematological profile, GSH content and life expectancy
[24].
We measured cytokine levels in whole blood culture
supernatants from healthy and HIV infected subjects. No
clear trend in cytokine profile was observed in healthy
subjects. Interestingly, we observed that in vitro infection
with H37Rv induced the whole blood cultures from HIV
patients to synthesize increased levels of cytokines such as
IL-1, TNF-α, IL-6 and IL-10 (Fig 4, 5). IL-1, TNF-α, IL-6 are
the early pro-inflammatory cytokines produced by mono-
cytes after various bacterial infections and share a wide
array of biological activities [4,5]. In vitro studies have
shown that mycobacterial preparations, including
lipoarabinomannan, can cause the release of TNF-α and
IL-1 from human PBMC [25,42,44].
The release of pro-inflammatory cytokines after mycobac-
terial infection is a host immune response that may be
propitious or deleterious to the host. Newman et al.
reported that increased survival of M. avium intracellulare
(MAI) in isolated macrophages is correlated with the effi-
ciency with which TNF-α and IL-6 are produced in
response to MAI infection [28]. Nevertheless, increased
levels of these pro-inflammatory cytokines may be disad-
vantageous to the host because they not only cause acute-
phase events, such as fever, but also mediate cachexia,
hemorrhagic necrosis and lethal shock [29,30,37]. TNF-α
by classical cascade is known to up-regulate the levels of
IL-1 and IL-6.
Elevated levels of IL-6 are present in plasma of patients
with TB [15]. Studies by Van Heyningen et al [39] indicate
that macrophages infected with M. bovis BCG released
copious amounts of IL-6 which in turn inhibited the mac-
rophage capacity to induce proliferation of CD4 T cell
hybridoma. Nagabhushanam et al. [26] reported a novel
function of IL-6 in inhibiting cellular immune response to
eradicate M. tuberculosis infection. Their studies show that
IL-6 produced by M. tuberculosis-infected macrophages
selectively inhibited macrophage responses to IFN-γ. In
other words, secretion of IL-6 by M. tuberculosis-infected
macrophages may contribute to the inability of IFN-γ to
eradicate M. tuberculosis infection [26].
The high levels of IL-6 released by infected macrophages
have implications for co-infection with HIV [32]. Myco-
bacterial infections are one of the most common AIDS-
defining illnesses and may even accelerate progression to
AIDS [17]. The two infections seem to synergize, causing
a shift of the host-pathogen balance in favor of the patho-
gen, which cannot be reversed by treatment with antimy-
cobacterial agents [43].
TNF-α and IL-6, as well as IL-1, can increase HIV replica-
tion [3,21]. Thus, decreasing the pro-inflammatory
cytokine production in vivo may enhance the control of
viral replication. Elevated levels of IL-6, TNF-α and IL-10
have been described previously in cases of advanced HIV
disease [1,20,22]. Therefore, increases in the levels of pro-
inflammatory cytokines will cause a positive feedback
loop in which the two infections complement one
another, leading to accelerated progression of both dis-
eases.
In our studies, we observed that NAC treatment caused
down-regulation of the synthesis of IL-1, IL-6, and TNF-α
(Fig 4a, 4b, 4c), and up-regulation of the synthesis of IFN-
γ (Fig 4d). These results suggest that GSH might have a
crucial role in vivo in reducing the levels of pro-inflamma-
tory cytokines thereby protecting the host against disease
progression.
Active TB is associated with suppression of T cell
responses [17] and enhanced production and activity of
immunosuppressive such as IL-10. IL-10 has been shown
to be produced by macrophages infected with mycobacte-
ria. IL-10 and TGF-β overlap with each other in many of
their biological effects including, inhibition of T cell pro-
liferation and IFN-γ production [21]. Elevated levels of IL-
10 in serum during advanced HIV infection may enhance
immune suppression, allowing opportunistic infections
[21]. In our studies, we observed that NAC treatment
decreased the levels of IL-10 favoring immune activation
(Fig 5b).
We demonstrate growth inhibition of intracellular H37Rv
in our in vitro studies using NAC-treated blood cultures
from HIV patients. Furthermore, treatment of blood cul-
tures with NAC modulated the production of cytokines in
favor of the host. As described in the model (Fig 6a), our
results strongly indicate that the immune cell enhancing
and antimycobacterial functions of GSH are important for
growth control of H37Rv in blood cultures from healthy
and HIV-infected subjects (Fig 6a). Additionally, NAC
treatment down-regulated the synthesis of IL-10 and pro-
inflammatory cytokines in blood cultures from HIV-
infected subjects favoring immune activation (Fig 6b).
Current interventions to prevent tuberculosis in areas
where TB and HIV are endemic, such as sub-Saharan
Africa, have serious limitations. ART is limited by its cost
and by its requirement for a sophisticated health care
delivery system. Isoniazid chemoprophylaxis has limited
efficacy in regions of high TB transmission, particularly in
highly susceptible individuals with advanced HIV infec-
tion. In addition, isoniazid is ineffective against INH-
resistant TB strains, which may account for 10–20% of all
cases in some areas. NAC is inexpensive and non-toxic (it
is considered a food supplement in the US, and is availa-AIDS Research and Therapy 2006, 3:5 http://www.aidsrestherapy.com/content/3/1/5
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ble without prescription in health food stores). The find-
ings from this study may lead to long-term research that
will be of potential importance for control of TB world-
wide.
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